London-headquartered biotech startup Verdiva has emerged from stealth with a whopping $410mn for a new range of drugs aimed at tackling the obesity epidemic. It’s one of Europe’s largest-ever biotech VC deals, signalling investor appetite for the booming weight loss market. Verdiva looks to challenge the dominance of Novo Nordisk and Eli Lilly, the makers of the two most popular weight loss drugs, Ozempic and Wegovy. The company promises to offer less invasive pills, instead of injectables. Its most advanced product is an oral-based GLP-1, a drug that curbs hunger. Verdiva was founded in July 2024 by executives of Aiolos…
This story continues at The Next WebRead More